Method for treating cancer
View Patent ↗A method for the treatment of cancer by administering a therapeutically effective amount of a cyclin-dependent kinase (CDK) inhibitor with a therapeutically effective amount of a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor (“B Cell CLL/Lymphoma 2”, or “BCL-2”). Administration of the CDK inhibitor and BCL-2 inhibitor can be simultaneous, successive or separate.
1. A method for the treatment of cancer, said method comprising administration of a therapeutically effective amount of a cyclin-dependent kinase inhibitor in combination with a therapeutically effective amount of a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor, wherein the cancer is diffuse large B-cell leukemia or small cell lung cancer.
2. A method of claim 1 , wherein the cyclin-dependent kinase inhibitor is dinaciclib or pharmaceutically acceptable salt thereof, and the B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor is ABT-199 or a pharmaceutically acceptable salt thereof.
3. A method of claim 2 , comprising intravenously administering dinaciclib and orally administering ABT-199.
4. A method of claim 3 , comprising intravenously administering about 6-28 mg/m 2 dinaciclib over a period of about 1-4 hours once every 5-9 days.
5. A method of claim 4 , comprising intravenously administering about 12-14 mg/m 2 dinaciclib over a period of about 1-4 hours once every 5-9 days.
6. A method of claim 5 , comprising intravenously administering about 12-14 mg/m 2 dinaciclib over a period of about 2 hours once every 5-9 days.
7. A method of claim 6 , comprising intravenously administering about 12-14 mg/m 2 dinaciclib over a period of about 2 hours once every 7 days.
8. A method of claim 3 , comprising intravenously administering about 30-70 mg/m 2 dinaciclib over a period of about 1-4 hours once every 18-24 days.
9. A method of claim 8 , comprising intravenously administering about 50 mg/m 2 dinaciclib over a period of about 1-4 hours once every 18-24 days.
10. A method of claim 9 , comprising intravenously administering about 50 mg/m 2 dinaciclib over a period of about 2 hours once every 18-24 days.
11. A method of claim 10 , comprising intravenously administering about 50 mg/m 2 dinaciclib over a period of about 2 hours once every 21 days.
12. A method of claim 3 , comprising daily orally administering ABT-199.
13. A method of claim 12 , comprising daily orally administering about 20-900 mg ABT-199.
14. A method of claim 13 , comprising daily orally administering about 20-400 mg ABT-199.
15. A method of claim 14 , comprising daily orally administering about 50-400 mg ABT-199.
16. A method of claim 15 , comprising daily orally administering about 50 mg ABT-199.
17. A pharmaceutical composition comprising a therapeutically effective amount of a cyclin-dependent kinase inhibitor; and a therapeutically effective amount of a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor.
18. A pharmaceutical composition of claim 17 , wherein the cyclin-dependent kinase inhibitor is dinaciclib or pharmaceutically acceptable salt thereof, and the B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor is ABT-199 or a pharmaceutically acceptable salt thereof.
19. A combination comprising a cyclin-dependent kinase inhibitor and a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor for use in the treatment of cancer, wherein the cancer is diffuse large B-cell leukemia or small cell lung cancer.
20. The combination of claim 19 wherein the cyclin-dependent kinase inhibitor is dinaciclib and the B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor is ABT-199.